Courier Capital LLC Trims Position in Eli Lilly and Company (NYSE:LLY)

Courier Capital LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,971 shares of the company’s stock after selling 382 shares during the quarter. Courier Capital LLC’s holdings in Eli Lilly and Company were worth $2,898,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. S.A. Mason LLC raised its position in shares of Eli Lilly and Company by 2.0% in the 4th quarter. S.A. Mason LLC now owns 1,786 shares of the company’s stock worth $1,041,000 after buying an additional 35 shares during the period. Highland Capital Management LLC raised its position in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Highland Capital Management LLC now owns 13,350 shares of the company’s stock worth $7,782,000 after buying an additional 360 shares during the period. Columbia Trust Co 01012016 raised its position in shares of Eli Lilly and Company by 3.8% in the 4th quarter. Columbia Trust Co 01012016 now owns 1,056 shares of the company’s stock worth $616,000 after buying an additional 39 shares during the period. Cresta Advisors Ltd. purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth $295,000. Finally, jvl associates llc raised its position in shares of Eli Lilly and Company by 44.1% in the 4th quarter. jvl associates llc now owns 588 shares of the company’s stock worth $343,000 after buying an additional 180 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 14,388 shares of Eli Lilly and Company stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $630.28, for a total transaction of $9,068,468.64. Following the sale, the insider now owns 99,754,422 shares of the company’s stock, valued at approximately $62,873,217,098.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 195,055 shares of company stock valued at $125,254,657 in the last quarter. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.5 %

Shares of NYSE LLY opened at $778.69 on Thursday. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock’s 50 day moving average price is $727.96 and its two-hundred day moving average price is $636.01. The stock has a market capitalization of $739.88 billion, a P/E ratio of 134.26, a PEG ratio of 1.70 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $334.58 and a 52-week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the business posted $2.09 EPS. On average, analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, February 20th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research report on Wednesday, February 21st. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Bank of America raised their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $689.52.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.